GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Policyholder Funds

InnoCare Pharma (HKSE:09969) Policyholder Funds


View and export this data going back to 2020. Start your Free Trial

Policyholder Funds only applies to insurance companies.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.